About the Management Team
 |
Randy Alexander, President and CEO
Randy Alexander is a long-time leader in the ophthalmic industry. As President and CEO, he consistently has created value, delivered growth and implemented new technology, including successfully launching four start-up companies.
This seasoned senior executive was most recently the CEO of IntraLase Inc., where under Mr. Alexander's management the start-up earned over $18 million in revenue in a little over four years.
Mr. Alexander also was instrumental in raising $75 million in capital for IntraLase.
Before joining IntraLase, Mr. Alexander was Senior Vice President of Chiron Vision, where through his guidance, he established Chiron Vision as a leader in the refractive surgery industry. At Chiron Vision, he created a $50 million refractive product line by identifying the LASIK surgical procedure and acquiring patents and instrumentation.
During his close to 30-year career in ophthalmology, Mr. Alexander has served as CEO of Pharmacia Intermedics and Senior Vice President, Sales & Marketing of CILCO. Mr. Alexander holds both a bachelor's and master's degrees in Biological Sciences from Marshall University. |
 |
Louis Bunn, Chief Financial Officer
Louis H. Bunn has over 15 years experience as a senior financial executive with development-stage medical device companies. He was instrumental in raising in excess of $80 million in venture equity and debt as well as being actively involved in developing and implementing strategies for growth and maximizing shareholder value.
Most recently, Mr. Bunn was Chief Financial Officer and Senior Vice President of Finance & Administration of 3F Therapeutics, Inc. a company that focused on tissue heart-valve products. 3F Therapeutics, Inc. was acquired by ATS Medical, Inc. in September 2006.
Previously, Mr. Bunn was Chief Financial Officer and General Manager of EndiCOR Medical, Inc. a company specializing in coronary catheter products. The company was acquired by Ev3, Inc. in 2002. Prior to EndiCOR, Mr. Bunn served as Vice President and Chief Financial Officer of SenDx Medical, Inc., a critical care diagnostic equipment company, which was acquired by Radiometer in 1998.
Prior to this, Mr. Bunn was Senior Audit Manager with Ernst & Young. Mr. Bunn has a BA in Business Administration from San Diego State University and is a certified public accountant.
|
 |
Ali Dahi, V.P. Process Development
Ali Dahi brings 25 years of domestic and international experience in ophthalmic industry to RVO, including roles as Vice President of Research & Development and Quality Assurance at SynergEyes, Vice President of Operations at PVG, Project Manager at Allergan, Process Engineer at SOLA Barnes/Hind, and Signet Armorlite. As a Co-Founder of SynergEyes, Inc., Mr. Dahi provided the science and methods of manufacturing for the first high Dk hybrid contact lens. As a Co-Founder of PVG in China, Mr. Dahi was responsible for building a state-of-the-art manufacturing facility for spectacle lenses.
Mr. Dahi holds numerous patents in the ophthalmology field and a B.S. in engineering from the University of Central Florida and M.S. degrees in engineering and management from the University of Louisiana and the University of California. |
 |
Lynne Archer, Vice President of Clinical Affairs
Lynne Archer has over 25 years experience in the field of clinical research. For the past 17 years, Ms. Archer has been exclusively involved in ophthalmic clinical research. Most recently, as Vice President of Clinical Science at Eyeonics, where she was responsible for developing and implementing the clinical strategy and was instrumental in obtaining the first FDA approved accommodating IOL.
Prior to Eyeonics, Ms. Archer was the Ophthalmic National Study Director for Pharmacia. While at Pharmacia Ms Archer was instrumental in the approval of the first FDA prostaglandin drug, Xalatan, for the treatment of glaucoma.
|
 |
Keith Holliday, Vice President of Research & Development
Keith Holliday has a strong background in solving optical problems in both industrial and academic settings. In his role as Director of Laser Technology at Advanced Medical Optics (and at VISX prior to AMO’s acquisition), he contributed to the advancement of AMO's portfolio of laser refractive products, including the development of laser hardware, laser system control algorithms, optical measurement devices and surgical procedures.
Prior to joining VISX, Dr. Holliday had worked primarily in academia. He obtained his first degree in Physics and Electronics from the University of St. Andrews in Scotland and a Ph.D. from the Laser Physics Centre at the Australian National University. He spent three years at the Swiss Federal Institute of Technology, where he was primarily involved with the utilization of optical materials, both polymers and crystals, to develop very high density, holographic, optical storage and computational systems. At the University of Strathclyde in Scotland, Dr. Holliday was a faculty member at the Optical Materials Research Centre where he led a group of scientists primarily investigating high gain and broadband laser gain media.
|
 |
Audrey Munnerlyn, Vice President of Regulatory Affairs
Audrey Munnerlyn has over 10 years of experience in regulatory affairs and clinical research in the field of refractive surgery. Most recently, Ms. Munnerlyn held the position of Director of Regulatory Affairs for the Corneal Refractive Surgery Group within Advanced Medical Optics, Inc. Previously, she held management positions in Clinical Research and Regulatory Affairs at VISX, Incorporated.
In these positions, Ms. Munnerlyn successfully gained U.S. Food and Drug Administration approvals for numerous technological advancements and new indications for the use of excimer laser vision correction. In her current role, she is responsible for developing strategies for Revision Optics' submissions to the FDA, as well as ensuring regulatory compliance with U.S. and worldwide regulatory agencies.
Ms. Munnerlyn has a degree in biochemistry from the University of California, San Diego, and spent seven years in basic biomedical research prior to entering the ophthalmology field.
|
|
